Arca
Skip to content
Tools
Tools

Warning Letter to TOMSCOUT

Medical Devices. See TOMSCOUT's company page or this site's inspections.

On Dec 16, 2025, FDA's CDRH sent TOMSCOUT a warning letter.

  • Letter date: Dec 16, 2025
  • Issued by: CDRH
  • Closeout: โ€”

The Letter

As posted on FDA.gov โ†—; cited 21 CFR sections link to their page.

WARNING LETTER

CMS# 720850

December 16, 2025

Dear Lim Tong Moi:

The United States Food and Drug Administration (FDA) has reviewed TOMSCOUTโ€™s (โ€œyour firmโ€) website (tomscout.com) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. ยง 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.

Our review of your firmโ€™s website revealed statements that these breast binders (example trade names: โ€œHigh-Performance Bandage Binderโ€, โ€œAll-Day Comfort Binderโ€, โ€œSwimming Binder Setโ€) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:

โ€ข Per your firmโ€™s website: โ€œBinders help reduce gender dysphoriaโ€ โ€ข Per your firmโ€™s website: "Using a chest binder to flatten the chest can help alleviate gender dysphoriaโ€ โ€ข Per your firmโ€™s website: "binding alleviates distress associated with gender dysphoriaโ€

Our review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. ยง 360) (e.g., โ€œour founder began a two-year redesign journeyโ€, โ€œDesigned with care by and for transmasc, non-binary & gender-diverse folksโ€). Under section 510 of the Act (21 U.S.C. ยง 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. ยง 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that you have not registered or listed these devices for fiscal year 2026.

Therefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. ยง 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. ยง 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. ยง 360(j)).

Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure and injunction.

Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.

Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective action (which must address systemic problems) that your firm has taken. If your firmโ€™s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firmโ€™s response(s) and the need to re-inspect your firmโ€™s facility to verify that the appropriate corrections and/or corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.

Your firmโ€™s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, โ€œCMS 720850โ€ when replying.

Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firmโ€™s facility. It is your firmโ€™s responsibility to ensure compliance with applicable laws and regulations administered by FDA.

Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.

Sincerely, /S/ Michael J. Hoffmann Director Office of Health Technology 3 - Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Food and Drug Administration

cc: Shopify, Inc. abuse@shopify.com

cc: hello@tomscout.com

The Firm's Other Letters

Same company or the same FDA site, newest first

Record

Recipient
Lim Tong Moi
FDA site ID (FEI)
3042195147
Cited
โ€”

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.